{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:09:26Z","timestamp":1780571366484,"version":"3.54.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Technologies Research and Development","award":["2022YFC2505000"],"award-info":[{"award-number":["2022YFC2505000"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite emerging genomic discoveries, few have been translated into practical management strategies for people with gastroenteropancreatic neuroendocrine carcinoma (GEPNEC). This study aims to identify key genes and their potential clinical relevance to improve care for this patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the analytical cohort, we reported high-frequency alteration genes, significantly mutated genes, and driver genes and defined their overlap as key genes. Genotypes were identified as Type I\/II\/III. For further validation, we prospectively recruited eligible patients to build a main cohort, through which we performed univariate\/multivariate Cox regression analysis and sketched Kaplan\u2013Meier survival plot. Targetable genes were defined by the OncoKB database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analytical cohort consisted of 124 patients. The genes most frequently altered were TP53 (78%), RB1 (35%), APC (27%), and KRAS (17%). Key genes were identified as TP53, RB1, APC, and KRAS. The main cohort included 171 patients. We defined the genotype \u201cType I\u201d (defined as TP53\/RB1 co-alterations) as a reference. In midgut\/hindgut NEC, we identified a \u201cType II\u201d subtype characterized by mutations in either APC or KRAS alterations without TP53\/RB1 co-alterations. Type II of midgut\/hindgut NEC patients had elevated carcinoembryonic antigen (CEA) levels and longer median overall survival (mOS) than others (not reached vs 11.4\u2009months, HR\u2009=\u20090.19[0.08, 0.44], P\u2009=\u2009.0028). In foregut NEC, we identified \u201cType III\u201d (either APC\/KRAS alterations or TP53\/RB1 co-alterations). Type III of foregut NEC patients showed shorter mOS than others (11.6 vs 19.0\u2009months, HR\u2009=\u20091.93[1.13, 3.25], P\u2009=\u2009.01). Type II patients who received non-platinum\/etoposide (EP) chemotherapy had longer first-line progression-free survival (PFS) compared to EP regimen. They also benefited from second-line immunotherapy. Targeted therapy as second-line was also suitable for targetable patients (longer PFS than others: 12.5 vs 3.0\u2009months, HR\u2009=\u20090.40[0.21-0.75], P\u2009=\u2009.0017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identified key gene-based genotypes (Type II\/III) of distinct GEPNEC patients and yielded their prognosis and therapeutic utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag185","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:42:52Z","timestamp":1778154172000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9943-9966","authenticated-orcid":false,"given":"Jianwei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]},{"name":"Department of Radiation Therapy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Shenzhen 518172,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Department, Nanjing Geneseeq Technology Inc. , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaomian","family":"Hu","sequence":"additional","affiliation":[{"name":"Medical Department, Nanjing Geneseeq Technology Inc. , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Department, Nanjing Geneseeq Technology Inc. , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing, China), Peking University Cancer Hospital and Institute , Beijing 100143,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026060406340401200_oyag185-B1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary Neuroendocrine Carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026060406340401200_oyag185-B2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ctrv.2012.06.009","article-title":"Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view","volume":"39","author":"Fazio","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2026060406340401200_oyag185-B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026060406340401200_oyag185-B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12022-024-09807-2","article-title":"Molecular classification of gastrointestinal and pancreatic neuroendocrine neoplasms: are we ready for that?","volume":"35","author":"Uccella","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026060406340401200_oyag185-B5","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"key":"2026060406340401200_oyag185-B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2017.04.002","article-title":"Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: a systematic review","volume":"56","author":"Girardi","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026060406340401200_oyag185-B7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"2026060406340401200_oyag185-B8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1159\/000512502","article-title":"ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC Pilot Study","volume":"111","author":"Gerard","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2026060406340401200_oyag185-B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clcc.2020.09.001","article-title":"Genetic characteristics of colorectal neuroendocrine carcinoma: more similar to colorectal adenocarcinoma","volume":"20","author":"Chen","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"2026060406340401200_oyag185-B10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"2026060406340401200_oyag185-B11","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/cac2.12372","article-title":"Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"2026060406340401200_oyag185-B12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.5858\/arpa.2020-0047-RA","article-title":"Recent advances in digestive tract tumors updates from the 5th edition of the World Health Organization \u201cBlue Book\u201d","volume":"145","author":"Gonzalez","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"2026060406340401200_oyag185-B13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026060406340401200_oyag185-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026060406340401200_oyag185-B15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","article-title":"Universal patterns of selection in cancer and somatic tissues","volume":"171","author":"Martincorena","year":"2017","journal-title":"Cell"},{"key":"2026060406340401200_oyag185-B16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"Aacr Project GENIE: Powering precision medicine through an international consortium","volume":"7","author":"Aacr Project G","year":"2017","journal-title":"Cancer Discov"},{"key":"2026060406340401200_oyag185-B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/annonc\/mdw005","article-title":"Clinical correlation of extensive-stage small-cell lung cancer genomics","volume":"27","author":"Dowlati","year":"2016","journal-title":"Ann Oncol"},{"key":"2026060406340401200_oyag185-B18","doi-asserted-by":"publisher","first-page":"653153","DOI":"10.3389\/fonc.2021.653153","article-title":"Prevalence of TP-53\/Rb-1 co-mutation in large cell neuroendocrine carcinoma","volume":"11","author":"Saghaeiannejad Esfahani","year":"2021","journal-title":"Front Oncol"},{"key":"2026060406340401200_oyag185-B19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","article-title":"The prognostic and therapeutic role of genomic subtyping by sequencing tumor or Cell-Free DNA in pulmonary Large-Cell neuroendocrine carcinoma","volume":"26","author":"Zhuo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026060406340401200_oyag185-B20","doi-asserted-by":"publisher","first-page":"9061","DOI":"10.1200\/JCO.2017.35.15_suppl.9061","article-title":"Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy","volume":"35","author":"Derks","year":"2017","journal-title":"JCO"},{"key":"2026060406340401200_oyag185-B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"2026060406340401200_oyag185-B22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/cac2.12372","article-title":"Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun"},{"key":"2026060406340401200_oyag185-B23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2020.10.023","article-title":"An organoid biobank of neuroendocrine neoplasms enables Genotype-Phenotype mapping","volume":"183","author":"Kawasaki","year":"2020","journal-title":"Cell"},{"key":"2026060406340401200_oyag185-B24","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1038\/s41388-018-0634-0","article-title":"Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer","volume":"38","author":"Wiesweg","year":"2019","journal-title":"Oncogene"},{"key":"2026060406340401200_oyag185-B25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1053\/j.gastro.2006.08.011","article-title":"APC and oncogenic KRAS are synergistic in enhancing wnt signaling in intestinal tumor formation and progression","volume":"131","author":"Janssen","year":"2006","journal-title":"Gastroenterology"},{"key":"2026060406340401200_oyag185-B26","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026060406340401200_oyag185-B27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/modpathol.2017.110","article-title":"Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations","volume":"31","author":"Rekhtman","year":"2018","journal-title":"Mod Pathol"},{"key":"2026060406340401200_oyag185-B28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/modpathol.3800659","article-title":"Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis","volume":"19","author":"Hiroshima","year":"2006","journal-title":"Mod Pathol"},{"key":"2026060406340401200_oyag185-B29","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026060406340401200_oyag185-B30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/cancers13040643","article-title":"Biomarkers of response to Etoposide\\u2011Platinum chemotherapy in patients with Grade 3 Neuroendocrine Neoplasms","volume":"13","author":"Lacombe","year":"2021","journal-title":"Cancers"},{"key":"2026060406340401200_oyag185-B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2021.04.030","article-title":"Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the groupe d\u2018Etude des tumeurs endocrines (GTE) and the ENDOCAN-RENATEN network","volume":"152","author":"Hadoux","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026060406340401200_oyag185-B32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1530\/ERC-22-0102","article-title":"Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study","volume":"29","author":"Hadoux","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026060406340401200_oyag185-B33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamaoncol.2020.8072","article-title":"Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas a review","volume":"7","author":"Stelwagen","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026060406340401200_oyag185-B34","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ijc.31828","article-title":"BRAF V600E mutation: a promising target in colorectal neuroendocrine carcinoma","volume":"144","author":"Dizdar","year":"2019","journal-title":"Int J Cancer"},{"key":"2026060406340401200_oyag185-B35","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/cancers13061485","article-title":"Antitumoral activity of the MEK inhibitor Trametinib (TMT212) alone and in combination with the CDK4\/6 inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells in vitro","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"key":"2026060406340401200_oyag185-B36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2169\/internalmedicine.2870-23","article-title":"BRAF V600E-mutated colorectal neuroendocrine carcinoma effectively treated with a chemotherapy protocol for BRAF-mutated metastatic colorectal cancer","volume":"63","author":"Owaki","year":"2024","journal-title":"Intern Med"},{"key":"2026060406340401200_oyag185-B37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"2026060406340401200_oyag185-B38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.lungcan.2019.05.015","article-title":"Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes","volume":"133","author":"Aredo","year":"2019","journal-title":"Lung Cancer"},{"key":"2026060406340401200_oyag185-B39","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.21873\/anticanres.12685","article-title":"Alterations of p53 and Rb pathways are associated with high proliferation in bladder urothelial carcinomas","volume":"38","author":"Goussia","year":"2018","journal-title":"Anticancer Res"},{"key":"2026060406340401200_oyag185-B40","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026060406340401200_oyag185-B41","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","article-title":"Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase ib trial","volume":"26","author":"Lu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026060406340401200_oyag185-B42","doi-asserted-by":"publisher","first-page":"e000438","DOI":"10.1136\/jitc-2019-000438","article-title":"Arid1a alterations function as a biomarker for longer progression\\u2011free survival after anti\\u2011PD\\u20111\/PD\\u2011L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag185\/68259861\/oyag185.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag185\/68259861\/oyag185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag185\/68259861\/oyag185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:34:07Z","timestamp":1780569247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag185\/8675012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag185","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,8]]},"article-number":"oyag185"}}